Nowadays, the improvement of the cardiorenal prognosis in patients with type 2 diabetes is largely independent of the current metabolic situation. The focus of patient-oriented treatment is on quality of life and organ protection. This is reflected in the current recommendations of the European and US diabetes societies (EASD/ADA) and in the practical recommendations of the German Diabetes Association (DDG). In addition, the European Society of Cardiology (ESC) has published evidence-based guidelines for the cardiorenal management of type 2 diabetics.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- Case study
Autosomal recessive polycystic kidney disease: atypical phenotype
- Current evidence, risk classes and new counseling options
Hormonal contraception and cardiovascular risk
- Acute otitis media: self-limiting course vs. "red flags"
In which cases are antibiotics necessary?
- Prurigo nodularis: evidence-based treatment
Targeted therapy options on the rise
- MACE risk, heart failure incidence and all-cause mortality
Metabolic syndrome as a cardiovascular risk factor
- Glaucoma in old age: slowing down progression
IOP lowering is currently the only evidence-based treatment
- Vector-borne infections with skin manifestations
Arboviruses and leishmaniasis in Europe
- Multimorbidity and functional capacity in old age